| Kloecker, Goetz H |
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy |
|
|
| Active, not recruiting | 3 | 758 | Europe, Canada, Japan, US, RoW | Cobolimab, Dostarlimab, Docetaxel | GlaxoSmithKline | Lung Cancer, Non-Small Cell | 04/25 | 10/25 | | |
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC). |
|
|
| Completed | 3 | 298 | Europe, Canada, US, RoW | NovoTTF-200M device, Best Standard of Care | NovoCure GmbH | Brain Metastases from Non-small Cell Lung Cancer (NSCLC) | 11/24 | 11/24 | | |
| Lenhardt, Rainer |
NCT05486416: Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery |
|
|
| Completed | 3 | 466 | Europe, US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 07/24 | 07/24 | | |
| Recruiting | 3 | 328 | Europe, Canada, US | TAK-330, SOC 4F-PCC | Takeda, Takeda Development Center Americas, Inc. | Coagulation Disorder | 04/28 | 04/28 | | |
COMBO, NCT03080896: Video-Laryngoscope Alone or With Bronchoscope for Predicted Difficult Intubation |
|
|
| Completed | N/A | 80 | US | King Vision video-laryngoscope with #3 disposable blade and endotracheal tube stylet, Ambu aScope III, fiberoptic bronchoscope aScope III, aScope III by Ambu | University of Louisville, Ambu A/S | Intubation; Difficult | 03/24 | 03/24 | | |
| Martin, Robert |
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC |
|
|
| Recruiting | 2 | 30 | US | RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq | Replimune Inc., Roche Pharma AG | Hepatocellular Carcinoma | 12/27 | 07/28 | | |
| Active, not recruiting | 1/2 | 42 | Europe, US | 1.0% IP-001 for Injection, IP-001 | Immunophotonics, Inc., Immunophotonics Inc. | Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma | 02/25 | 02/25 | | |
NCT05953337: Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | N/A | 120 | US | EYE90 Microspheres Treatment | ABK Biomedical | Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer | 10/25 | 10/25 | | |
CYBRID-02, NCT05520099: Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform |
|
|
| Recruiting | N/A | 216 | US | Core Needle or Forceps Biopsy | Elephas, Hoosier Cancer Research Network | Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Cutaneous Melanoma, Endometrial Cancer, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma | 01/27 | 01/27 | | |
| Dryden, Gerald W |
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease |
|
|
| Recruiting | 4 | 150 | Canada, US | Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara | Takeda | Crohn's Disease | 06/27 | 06/27 | | |
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) |
|
|
| Recruiting | 4 | 65 | Canada, US | Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550 | Takeda | Ulcerative Colitis | 07/27 | 07/27 | | |
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS |
|
|
| Completed | 2 | 216 | US, RoW | CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo | CalciMedica, Inc. | Acute Pancreatitis, Systemic Inflammatory Response Syndrome | 05/24 | 05/24 | | |
| Clark, Laura |
| Active, not recruiting | 2/3 | 186 | NA | Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo | Zydus Therapeutics Inc., Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 05/25 | 05/25 | | |
| Active, not recruiting | 2 | 180 | US, RoW | Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent | Zydus Therapeutics Inc. | Nonalcoholic Steatohepatitis, Fibrosis | 07/25 | 07/25 | | |
| Recruiting | 2 | 180 | Europe, Canada, Japan, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Biliary Cholangitis, PBC | 12/25 | 12/25 | | |
NCT02799485: sEphB4-HSA in Treating Patients With Kaposi Sarcoma |
|
|
| Active, not recruiting | 2 | 23 | US | Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Recombinant EphB4-HSA Fusion Protein, sEphB4-HSA | AIDS Malignancy Consortium, National Cancer Institute (NCI), Vasgene Therapeutics, Inc, The Emmes Company, LLC, University of Arkansas | Skin Kaposi Sarcoma | 12/25 | 06/26 | | |
| Active, not recruiting | 1 | 15 | US | Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine, LEUROCRISTINE, VCR, Vincrystine, Vincristine Sulfate, Kyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate | AIDS Malignancy Consortium, National Cancer Institute (NCI), Janssen Scientific Affairs, LLC, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, AIDS and Cancer Specimen Resource, The Emmes Company, LLC | Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | 07/25 | 08/27 | | |
| Liu, Wei |
NCT02864953 / 2017-004854-41: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction |
|
|
| Terminated | 3 | 535 | Europe, Canada, Japan, US, RoW | BIIB093, glibenclamide, glibenclamide intravenous (IV), glyburide, CIRARA, Placebo | Remedy Pharmaceuticals, Inc. | Brain Edema, Stroke, Acute | 08/23 | 08/23 | | |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
NCT06434467: The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma |
|
|
| Not yet recruiting | 3 | 83 | RoW | Nelarabine injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma | 12/25 | 05/26 | | |
| Completed | 2 | 3 | RoW | ICP-022 | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma | 11/21 | 12/21 | | |
NCT05346146: A Prospective, Single-arm, Exploratory Clinical Study of Sintilimab Injection in Combination With Paclitaxel (Albumin-bound) and Gemcitabine in Translational Therapy in Patients With Unresectable Locally Advanced Pancreatic Cancer. |
|
|
| Recruiting | 2 | 20 | RoW | Sintilimab; Gemcitabine; Albumin-paclitaxel | RenJi Hospital, Innovent Biologics (Suzhou) Co. Ltd. | Unresectable Locally Advanced Pancreatic Cancer | 07/23 | 07/24 | | |
NCT05997602: To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH |
|
|
| Recruiting | 2 | 56 | RoW | FCN-159 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Langerhans Cell Histiocytosis, LCH | 07/24 | 07/26 | | |
NCT04690192: CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma |
|
|
| Active, not recruiting | 1/2 | 20 | RoW | CNCT19, Gemcitabine Injection, busulfan, Melphalan Injection | Zou Dehui, Juventas Cell Therapy Ltd. | Large B-cell Lymphoma | 12/23 | 12/24 | | |
NCT04464551: The Absorption, Metabolism and Excretion of [14C]D-0316 in Human |
|
|
| Active, not recruiting | 1 | 4 | RoW | [14C]D-0316 suspension | Betta Pharmaceuticals Co., Ltd. | Advanced or Metastatic Non-small Cell Lung | 08/21 | 08/21 | | |
NCT04696705: Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients |
|
|
| Recruiting | 1 | 10 | RoW | Ex-vivo expanded allogeneic γδT cells | Institute of Hematology & Blood Diseases Hospital, Beijing GD Initiative Cell Therapy Technology Co., Ltd., Chinese Academy of Medical Sciences | Non-Hodgkin's Lymphoma (NHL), Peripheral T Cell Lymphoma (PTCL) | 12/21 | 12/23 | | |
| Active, not recruiting | 1 | 18 | RoW | Liposomal Mitoxantrone Hydrochloride dose level 1, Liposomal Mitoxantrone Hydrochloride dose level 2, Liposomal Mitoxantrone Hydrochloride dose level 3, Liposomal Mitoxantrone Hydrochloride dose level 4 | Institute of Hematology & Blood Diseases Hospital, China, CSPC Ouyi Pharmaceutical Co., Ltd. | Non Hodgkin Lymphoma | 12/23 | 12/25 | | |
NCT05318963: Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma |
|
|
| Recruiting | 1 | 34 | RoW | LCAR-AIO cells product | Qiu Lugui, Nanjing Legend Biotech Co. | B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | 06/24 | 06/26 | | |
NCT04853238: Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China |
|
|
| Completed | N/A | 1507 | RoW | Prospective observational cohort study | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 11/22 | 02/23 | | |
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus |
|
|
| Recruiting | N/A | 184 | RoW | Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter | Shanghai Bluesail Boyuan Medical Technology Co., Ltd. | Coronary Artery Disease, Intravascular Lithotripsy | 12/24 | 09/25 | | |
| Redman, Rebecca |
| Recruiting | 2 | 45 | US | Pembrolizumab, KEYTRUDA®, MK-3475, Olaparib, AZD-2281, MK-7339, KU0059436, Cisplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-platinum, IMRT (intensity modulated radiation therapy) | UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC | Squamous Cell Carcinoma of Head and Neck | 10/25 | 10/26 | | |
| Active, not recruiting | 1/2 | 323 | US, RoW | FLX475, pembrolizumab (KEYTRUDA®) | RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC | Advanced Cancer | 09/24 | 01/25 | | |
| Recruiting | 1/2 | 242 | US | DF9001, pembrolizumab, KEYTRUDA® | Dragonfly Therapeutics, Merck Sharp & Dohme LLC | Solid Tumor, Adult | 08/25 | 11/27 | | |
NCT02922764: A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer |
|
|
| Active, not recruiting | 1 | 146 | US | RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed | Inspirna, Inc. | Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma | 12/24 | 12/24 | | |
|
| Terminated | 1 | 64 | US | MT-6402 | Molecular Templates, Inc. | Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck | 10/24 | 10/24 | | |
| Recruiting | 1 | 47 | US | CHS-114, toripaliamab, Loqtorzi | Coherus Biosciences, Inc. | Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma | 02/26 | 02/26 | | |
|
| Contact, Central |
NCT03641560: A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy |
|
|
| Completed | 4 | 52 | RoW | Enzalutamide, MDV3100, Xtandi, Androgen deprivation therapy (ADT) | Astellas Pharma Inc | Metastatic Castration Resistant Prostate Cancer | 02/24 | 02/24 | | |
| Recruiting | 4 | 30 | US | IgPro10, Privigen | CSL Behring | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 12/29 | 12/29 | | |
NCT02294461: An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants |
|
|
| Completed | 3 | 395 | RoW | Enzalutamide, Xtandi, MDV3100, Placebo | Astellas Pharma Inc | Progressive Metastatic Prostate Cancer | 09/15 | 07/24 | | |
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS |
|
|
| Recruiting | 3 | 177 | Canada, US | IgPro20, HIZENTRA®, Placebo | CSL Behring | Post-COVID Postural Orthostatic Tachycardia Syndrome | 09/27 | 09/27 | | |
NCT06617897: Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery |
|
|
| Recruiting | 3 | 90 | Europe | CSL511 Fibrinogen concentrate (human), Cryoprecipitate | CSL Behring | Acquired Fibrinogen Deficiency | 09/26 | 10/26 | | |
TAP, NCT05568888: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( Study ) |
|
|
| Terminated | 3 | 1370 | Europe, US, RoW | BE1116, 4-Factor Prothrombin Complex, Kcentra®, Beriplex®, Placebo | CSL Behring | Traumatic Injury | 10/24 | 10/24 | | |
NCT02430220: The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 152 | RoW | Regorafenib (CT), BAY 73-4506, Regorafenib (STIVARGA) | Cancer Centre of Monoclonal Therapy, LLC, Clinical Cancer Hospital, Bayer | Solid Tumors, Colorectal Cancer | 04/18 | 09/18 | | |
| Active, not recruiting | 2 | 100 | US | ALG-055009, Placebo | Aligos Therapeutics | NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis | 11/24 | 12/24 | | |
NCT06545916: Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder |
|
|
| Recruiting | 2 | 200 | US | Sunobinop, V117957, Placebo to match sunobinop | Imbrium Therapeutics, Purdue Pharma LP | Alcohol Use Disorder | 07/25 | 07/25 | | |
NCT06285214: Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome |
|
|
| Completed | 1 | 47 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Interstitial Cystitis/Bladder Pain Syndrome | 01/25 | 01/25 | | |
NCT04285827: Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease |
|
|
| Completed | 1 | 28 | Europe, US | CSL889 | CSL Behring | Sickle Cell Disease | 07/23 | 07/23 | | |
| Recruiting | 1 | 174 | US | PRL-02 injection, prednisone, dexamethasone, enzalutamide | Astellas Pharma Global Development, Inc. | Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer | 08/25 | 05/29 | | |
NCT06364696: A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors |
|
|
| Recruiting | 1 | 175 | US | ASP4396 | Astellas Pharma Inc | Solid Tumor | 04/27 | 04/27 | | |
| Recruiting | 1 | 229 | US | ASP1012, Pembrolizumab | Astellas Pharma Global Development, Inc. | Solid Tumor | 06/29 | 06/29 | | |
NCT06248086: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas |
|
|
| Terminated | 1 | 1 | RoW | ASP2802, MACT, MA-20, ASP101G, MicAbody | Astellas Pharma Global Development, Inc. | B-cell Lymphoma | 12/24 | 12/24 | | |
NCT06024642: Study of V117957 in Overactive Bladder Syndrome |
|
|
| Completed | 1 | 51 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Overactive Bladder Syndrome | 05/24 | 05/24 | | |
| Completed | N/A | 1443 | US | | Shire | Hunter Syndrome | 02/23 | 02/23 | | |
| Recruiting | N/A | 1257 | US | | Shire | Gaucher Disease | 09/25 | 09/25 | | |
NCT06734585: Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant |
|
|
| Recruiting | N/A | 200 | RoW | Gilteritinib, ASP2215, XOSPATA® | Astellas Pharma Singapore Pte. Ltd. | Acute Myeloid Leukemia | 06/25 | 06/25 | | |
OPTION-VMS, NCT06049797: A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats |
|
|
| Recruiting | N/A | 1000 | US | Fezolinetant, ESN364, VEOZAH, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above | Astellas Pharma Global Development, Inc. | Hot Flashes | 02/26 | 11/26 | | |
NCT03971253: Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis |
|
|
| Recruiting | N/A | 3000 | Japan | Peficitinib, ASP015K, Smyraf | Astellas Pharma Inc | Rheumatoid Arthritis (RA) | 12/25 | 12/25 | | |
NCT05886348: The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens |
|
|
| Active, not recruiting | N/A | 249 | RoW | Model-A Novel spectacle lens, Model-B Novel spectacle lens, Single vision spectacle lens | HOYA Lens Thailand LTD. | Myopia | 05/26 | 05/27 | | |
NCT06011954: A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection |
|
|
| Recruiting | N/A | 202 | RoW | Enfortumab Vedotin, PADCEV, ASG-22CE | Astellas Pharma Korea, Inc., Seagen Inc. | Urothelial Cancer | 07/27 | 07/27 | | |
| Rogers, Benjamin |
diSArm, NCT05184764: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia |
|
|
| Recruiting | 1/2 | 50 | US, RoW | AP-SA02, Placebo | Armata Pharmaceuticals, Inc., United States Department of Defense | Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus | 12/24 | 03/25 | | |
| Saad, Mohamed |
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 698 | Canada, US, RoW | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Progressive Pulmonary Fibrosis, Interstitial Lung Disease | 11/27 | 11/27 | | |
NCT05571059: Oral Ifetroban in Patients with Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Recruiting | 2 | 128 | US | Ifetroban Sodium, ifetroban, Placebo | Cumberland Pharmaceuticals | Idiopathic Pulmonary Fibrosis | 01/26 | 01/26 | | |
RESCUE3, NCT03783884: A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning From Mechanical Ventilation |
|
|
| Terminated | N/A | 223 | Europe, US | Lungpacer Diaphragm Pacing Therapy, Lungpacer DPTS, AeroPace System | Lungpacer Medical Inc. | Ventilator Induced Diaphragm Dysfunction | 12/22 | 01/23 | | |
| Morris, Marvin E |
| Active, not recruiting | N/A | 60 | US | ASC coated ePTFE vascular graft, TGI PVG, Propaten graft, item HT060080A | Tissue Genesis | Lower Limb Ischemia | 04/22 | 05/22 | | |
| Smith, Jason |
| Terminated | N/A | 12500 | Europe, Canada, US, RoW | | Arthrex, Inc. | Degenerative and Traumatic Pathology of the Knee, Degenerative and Traumatic Pathology of the Shoulder and Elbow, Degenerative and Traumatic Pathology of the Foot and Ankle, Degenerative and Traumatic Pathology of the Hand and Wrist, Degenerative and Traumatic Pathology of the Hip | 07/23 | 07/23 | | |
| Completed | N/A | 692 | Europe, US | Catheter-Directed Thrombolysis, FlowTriever System | Inari Medical | Pulmonary Embolism, Pulmonary Thrombo-embolism | 03/24 | 04/24 | | |
| Francis, Sean L |
NCT04845217: Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome |
|
|
| Recruiting | 1/2 | 100 | US | Peppermint oil, Peptogest Peppermint Oil, Coconut Oil, Coconut Oil Pure Extra Virgin | University of Louisville, Integrative Therapeutics, Inc. | Interstitial Cystitis | 06/23 | 12/23 | | |
| Recruiting | N/A | 300 | US | Desara® One Single Incision Sling, Desara® Blue Transobturator Sling | Caldera Medical, Inc. | Stress Urinary Incontinence | 11/26 | 11/26 | | |
| Candiotti, Keith |
NCT05486416: Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery |
|
|
| Completed | 3 | 466 | Europe, US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 07/24 | 07/24 | | |
| Rosenbaum, David P |
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
|
|
| Recruiting | 3 | 180 | US | Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | 12/25 | 12/25 | | |
NCT05905926: Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C |
|
|
| Enrolling by invitation | 3 | 150 | US | Tenapanor, Ibsrela | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | 07/31 | 10/31 | | |
NCT06553547: 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs |
|
|
| Recruiting | 2 | 72 | US | Tenapanor, IBSRELA, Placebo | Ardelyx | Irritable Bowel Syndrome with Constipation (IBS-C) | 06/26 | 06/26 | | |
| Recruiting | N/A | 168 | Europe, US | Tigertriever 13 | Rapid Medical | Ischemic Stroke, Neovascularization | 03/25 | 03/25 | | |
NCT04129125: The Imperative Trial: Treatment of Acute Ischemic Stroke With the Zoom Reperfusion System |
|
|
| Completed | N/A | 328 | US | Zoom Reperfusion System | Imperative Care, Inc. | Ischemic Stroke, Acute Stroke | 05/24 | 05/24 | | |
| Slaughter, Mark |
COMPETENCE, NCT01187368: Prospective Multi-Center Randomized Study for Evaluating the EVAHEART®2 Left Ventricular Assist System |
|
|
| Suspended | N/A | 399 | US | EVAHEART Left Ventricular Assist System (LVAS), EVA2, HeartMate 3, HM3 | Evaheart, Inc. | Heart Failure | 07/27 | 07/28 | | |
| Recruiting | N/A | 650 | Europe, Canada, Japan, US, RoW | Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT) | Medtronic Cardiovascular | Moderate Aortic Valve Stenosis | 02/26 | 12/34 | | |
| Recruiting | N/A | 6500 | Europe, Canada, US | AtriClip LAA Exclusion System | AtriCure, Inc., Population Health Research Institute | Ischemic Stroke, Systemic Embolism | 12/31 | 04/32 | | |
| Asaithambi, Ganesh |
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis |
|
|
| Recruiting | 3 | 1683 | US | Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management | University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca | Intracranial Arteriosclerosis, Stroke | 05/28 | 05/28 | | |
| Recruiting | 2 | 300 | US | TS23 | Translational Sciences, Inc., University of Cincinnati, National Institute of Neurological Disorders and Stroke (NINDS), Medical University of South Carolina, University of Arizona | Ischemic Stroke | 07/27 | 12/27 | | |
| Jerde, Ann |
| Completed | N/A | 1057 | Canada, US | NeuroBlate System | Monteris Medical | Metastatic Brain Tumor, Primary Brain Tumor, Epileptic/Seizure Foci, Movement Disorders | 09/23 | 09/23 | | |
NCT05075850: Multicenter Sub-study for LAANTERN Registry NCT02392078 That Will Include Comprehensive Neuropsychological Assessment Data Collection |
|
|
| Completed | N/A | 87 | NA | Neuroblate System | Monteris Medical | Cognitive Change | 09/23 | 09/23 | | |
| Cooke, Elizabeth |
COMBO, NCT03080896: Video-Laryngoscope Alone or With Bronchoscope for Predicted Difficult Intubation |
|
|
| Completed | N/A | 80 | US | King Vision video-laryngoscope with #3 disposable blade and endotracheal tube stylet, Ambu aScope III, fiberoptic bronchoscope aScope III, aScope III by Ambu | University of Louisville, Ambu A/S | Intubation; Difficult | 03/24 | 03/24 | | |
| Suliman, Sally |
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 576 | Canada, US | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 06/25 | 06/25 | | |
|
|
| Stolarski, Edward |
NCT04636229: Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee |
|
|
| Active, not recruiting | 3 | 474 | US | Amniotic Suspension Allograft, Placebo | Organogenesis, Premier Research Group plc | Knee Osteoarthritis | 07/23 | 03/24 | | |
NCT05478174: Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia |
|
|
| Completed | 3 | 400 | US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 11/23 | 11/23 | | |
NCT06269705: ZILRETTA in Subjects with Shoulder Osteoarthritis |
|
|
| Recruiting | 3 | 250 | US | ZILRETTA, TCA-IR, Placebo, Normal Saline | Pacira Pharmaceuticals, Inc | Glenohumeral Osteoarthritis | 08/25 | 08/25 | | |
NCT05486416: Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery |
|
|
| Completed | 3 | 466 | Europe, US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 07/24 | 07/24 | | |
| Completed | 2 | 76 | US | VT-X7 Treatment System, Two-stage exchange arthroplasty, SOC Antibiotics, Experimental Antibiotics | Osteal Therapeutics, Inc. | Prosthetic-joint Infection | 05/24 | 10/24 | | |
NCT04763759: Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections |
|
|
| Completed | 1 | 15 | US | TRL1068, a human monoclonal antibody | Trellis Bioscience LLC, University of California, Los Angeles, Biomedical Advanced Research and Development Authority, Wellcome Trust, Sinai Hospital of Baltimore, Gulfcoast Research Institute, Phoenix Clinical Research, University of Florida, University of Alabama at Birmingham, The Methodist Hospital Research Institute, University of Virginia, University of Southern California | Prosthetic Joint Infection | 03/24 | 03/24 | | |
| Brown, Molly |
| Active, not recruiting | N/A | 750 | NA | | Dot Laboratories, Inc. | Endometriosis | 05/23 | 12/24 | | |
| Berkowitz, Richard |
NCT05478174: Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia |
|
|
| Completed | 3 | 400 | US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 11/23 | 11/23 | | |
NCT05486416: Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery |
|
|
| Completed | 3 | 466 | Europe, US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 07/24 | 07/24 | | |
NCT04763759: Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections |
|
|
| Completed | 1 | 15 | US | TRL1068, a human monoclonal antibody | Trellis Bioscience LLC, University of California, Los Angeles, Biomedical Advanced Research and Development Authority, Wellcome Trust, Sinai Hospital of Baltimore, Gulfcoast Research Institute, Phoenix Clinical Research, University of Florida, University of Alabama at Birmingham, The Methodist Hospital Research Institute, University of Virginia, University of Southern California | Prosthetic Joint Infection | 03/24 | 03/24 | | |
| Mockoviak, Jennifer |
NCT05478174: Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia |
|
|
| Completed | 3 | 400 | US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 11/23 | 11/23 | | |
NCT05486416: Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery |
|
|
| Completed | 3 | 466 | Europe, US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 07/24 | 07/24 | | |
| CHEADLE, WILLIAM G |
| No trials found |
| Winrich, Evan J |
| No trials found |
| Tiwari, Harsh |
| No trials found |
| Rashid, Salwa M |
| No trials found |
